Study on the efficacy of octreotide acetate for cancer-related bowel obstruction
Ontology highlight
ABSTRACT: Interventions: Octreotide acetate of 300 ug/day is administered primarily as a continuous subcutaneous infusion using a continuous infusion pump. Dosage is fixed at 300 ug/day until Day 4. In patients extubated by Day 4, dosage is fixed at 300 ug/day until Day 7.
Primary outcome(s): Amelioration of abdominal symptoms (subjective parameters)
Study Design: Single arm Non-randomized
DISEASE(S): Cancer-related Bowel Obstruction
PROVIDER: 2616030 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA